Gene targeting in the analysis of mammalian apoptosis and TNF receptor superfamily signaling

Immunological Reviews

Volumn 169, Issue , 1999, Pages 283-302

  Yeh, Wen Chen ^a   Hakem, Razqallah ^a   Woo, Minna ^a   Mak, Tak W ^a  

^a AMGEN INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR NECROSIS FACTOR RECEPTOR;

APOPTOSIS; CELL PROLIFERATION; GENE TARGETING; KNOCKOUT MOUSE; MOUSE; NONHUMAN; ORGANOGENESIS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; APOPTOSIS; APOPTOTIC PROTEASE-ACTIVATING FACTOR 1; CARRIER PROTEINS; CASPASES; FAS-ASSOCIATED DEATH DOMAIN PROTEIN; GENE TARGETING; GENES, BCL-2; HUMANS; MICE; MICE, KNOCKOUT; MODELS, BIOLOGICAL; PROTEINS; RECEPTORS, TUMOR NECROSIS FACTOR; SIGNAL TRANSDUCTION; TNF RECEPTOR-ASSOCIATED FACTOR 6;

EID: 0032776185     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-065X.1999.tb01323.x     Document Type: Review

References (184)

1. 1. Raff M. Cell suicide for beginners. Nature 1998;396:119-122.
2. 2. Nicholson DW, Thornberry NA. Caspases: killer proteases. Trends Biochem Sci 1997;22:299-306.
3. 3. Thornberry NA, Lazebnik Y. Caspases: enemies within. Science 1998;281:1312-1316.
4. 4. Ellis RE, Horvitz HR. Two C. elegans genes control the programmed deaths of specific cells in the pharynx. Development 1991:112:591-603.
5. 5. Yuan J, Horvitz HR. The Caenorhabditis elegans cell death gene ced-4 encodes a novel protein and is expressed during the period of extensive programmed cell death. Development 1992;116:309-320.
6. 6. Yuan JY. Horvitz HR. The Caenorhabditis elegans genes ced-3 and ced 4 act cell autonomously to cause programmed cell death. Dev Biol 1990;138:33-41.
7. 7. Spector MS, Desnoyers S, Hoeppner DJ, Hengartner MO. Interaction between the C. elegans cell-death regulators CED-9 and CED-4. Nature 1997;385:653-656.
8. 8. Chinnaiyan AM, O'Rourke K, Lane BR, Dixit VM. Interaction of CED 4 with CED-3 and CED-9: a molecular framework for cell death. Science 1997;275:1122-1126.
9. 9. Wu D, Wallen HD, Inohara N, Nunez G. Interaction and regulation of the Caenorhabditis elegans death protease CED-3 by CED-4 and CED-9. J Biol Chem 1997;272:21449-21454.
10. 10. Alnemri ES, et al. Human ICE/CED-3 protease nomenclature. Cell 1996:87:171.
11. 11. Hu S, Snipas SJ, Vincenz C, Salvesen G, Dixit VM. Caspase 14 is a novel developmentally regulated protease. J Biol Chem 1998;273:29648-29653.
12. 12. Zou H, Henzel WJ, Liu X, Lutschg A, Wang X. Apaf-1, a human protein homologous to C, elegans CED-4, participates in cytochrome c-dependent activation of caspase-3. Cell 1997;90:405-413.
13. 13. Green DR, Reed JC. Mitochondria and apoptosis. Science 1998;281:1309-1311.
14. 14. Cohen GM. Caspases: the executioners of apoptosis. Biochem J 1997;326:1-16.
15. 15. Steller H. Mechanisms and genes of cellular suicide. Science 1995;267:1445-1449
16. 16. Xue D, Shaham S, Horvitz HR. The Caenorhabditis elegans cell-death protein CED-3 is a cysteine protease with substrate specificities similar to those of the human CPP32 protease. Genes Dev 1996;10:1073-1083.
17. 17. Fernandes-Alnemri T, Litwack G, Alnemri ES. CPP32, a novel human apoptotic protein with homology to Caenorhabditis elegans cell death protein Ced-3 and mammalian interleukin-1 β-converting enzyme. J Biol Chem 1994;269:30761-30764.
18. 18. Tewari M. et al. Yama/CPP32 β, a mammalian homolog of CED 3, is a CrmA-inhihitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. Cell 1995;81:801-809.
19. 19. Schlegel J, et al. CPP32/apopain is a key interleukin 1 β converting enzyme-like protease involved in Fas-mediated apoptosis. J Biol Chem 1996;271:1841-1844.
20. 20. Darmon AJ, Nicholson DW, Bleackley RC. Activation of the apoptotic protease CPP32 by cytotoxic T-cell-derived granzyme B. Nature 1995;377:446-448.
21. 21. Quan LT, et al. Proteolytic activation of the cell death protease Yama/CPP32 by granzyme B. Proc Natl Acad Sci USA 1996;93:1972-1976.
22. 22. Chao DT, Korsmeyer SJ. BCL-2 family: regulators of cell death. Annu Rev Immunol 1998;16:395-419.
23. 23. Inohara N, et al. Diva, a Bcl-2 homologue that binds directly to Apaf-1 and induces BH3-independent cell death J Biol Chem 1998; 273:32479-32486.
24. 24. Bakhshi A, et al. Cloning the chromosomal breakpoint of t(14;18) human lymphomas: clustering around JH on chromosome 14 and near a transcriptional unit on 18. Cell 1985;41:899-906.
25. 25. Tsujimoto Y, Cossman J, Jaffe E, Croce CM. Involvement of the bcl-2 gene in human follicular lymphoma. Science 1985;228:1440-1443.
26. 26. McDonnell TJ, Korsmeyer SJ. Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14;18). Nature 1991;349:254-256.
27. 27. McDonnell TJ, et al. bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell 1989;57:79-88.
28. 28. Linette GP, Hess JL, Sentman CL, Korsmeyer SJ. Peripheral T-cell lymphoma in lckpr bcl-2 transgenic mice. Blood 1995;86:1255-1260.
29. 29. Jaeger R, Herzer U, Schenkel J, Weiher H. Overexpression of Bcl-2 inhibits alveolar cell apoptosis during involution and accelerates c-myc-induced tumorigenesis of the mammary gland in transgenic mice. Oncogene 1997;15:1787-1795.
30. 30. Liu X, Kim CN, Yang J, Jemmerson R, Wang X. Induction of apoptotic program in cell free extracts: requirement for dATP and cytochrome c. Cell 1996;86:147-157.
31. 31. Srinivasula SM, Ahmad M, Fernandes-Alnemri T, Alnemri ES. Autoactivation of procaspase-9 by Apaf-1-mediated oligomerization. Mol Cell 1998;1:949-957.
32. 32. Hu Y, Benedict MA, Wu D, Inohara N, Nunez G. Bcl-XL interacts with Apaf-1 and inhibits Apaf-1-dependent caspase-9 activation. Proc Natl Acad Sci USA 1998;95:4386-4391.
33. 33. Perkins C, Kim CN, Fang G, Bhalla KN. Overexpression of Apaf-1 promotes apoptosis of untreated and paclitaxel-or etoposide-treated HL 60 cells. Cancer Res 1998;58:4561-4566.
34. 34. Mignotte B, Vayssiere JL. Mitochondria and apoptosis. Eur J Biochem 1998;252:1-15.
35. 35. Zamzami N, et al. Reduction in mitochondrial potential constitutes an early irreversible step of programmed lymphocyte death in vivo. J Exp Med 1995;181:1661-1672.
36. 36. Reed JC. Cytochrome c; can't live with it - can't live without it. Cell 1997;91:559-562.
37. 37. Kroemer G, ZamZami N, Susin SA. Mitochondrial control of apoptosis. Immunol Today 1997;18:44-51.
38. 38. Susin SA, et al. The central executioner of apoptosis: multiple connections between protease activation and mitochondria in Fas/APO-1/CD95-and ceramide-induced apoptosis. J Exp Med 1997;186:25-37.
39. 39. Yang J, et al. Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science 1997;275:1129-1132.
40. 40. Kluck RM, Bossy WE, Green DR, Newmeyer DD. The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science 1997;275:1132-1136.
41. 41. Rosse T, et al. Bcl-2 prolongs cell survival after Bax-induced release of cytochrome c. Nature 1998;391:496-499.
42. 42. Jurgensmeier JM, Xie Z, Deveraux Q, Ellerby L, Bredesen D, Reed JC. Bax directly induces release of cytochrome c from isolated mitochondria. Proc Natl Acad Sci USA 1998;95:4997-5002.
43. 43. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog. Bax, that accelerates programmed cell death. Cell 1993;74:609-619.
44. 44. Hu Y, Benedict MA, Wu D, Inohara N, Nunez G. Bcl-XI, interacts with Apaf-1 and inhibits Apaf-1-dependent caspase-9 activation. Proc Natl Acad Sci USA 1998;95:4386-4391.
45. 45. Pan G, O'Rourke K, Dixit VM. Caspase-9, Bcl-XI, and Apaf-1 form a ternary complex. J Biol Chem 1998;273:5841-5845.
46. 46. Cheng EH, et al. Conversion of Bcl-2 to a Bax-like death effector by caspases. Science 1996:178;1966-1968.
47. 47. Dhein J, Walczak H, Bacumler C, Debatin KM, Krammer PH. Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). Nature 1995;373:438-441.
48. 48. Ogasawara J, et al. Lethal effect of the anti-Fas antibody in mice [published erratum appears in Nature 1995;365:568]. Nature 1995;364:806-809.
49. 49. Galle PR, et al. Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage. J Exp Med 1995;182:1223-1230.
50. 50. Kondo T, Suda T, Fukuyama H, Adachi M, Nagata S. Essential roles of the Fas ligand in the development of hepatitis. Nat Med 1997;3:409-413.
51. 51. Adachi M, et al. Targeted mutation in the Fas gene causes hyperplasia in peripheral lymphoid organs and liver. Nat Genet 1995;11:294-300.
52. 52. Watanabe Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 1992;356:314-317.
53. 53. Jones RA, et al. Fas mediated apoptosis in mouse hepatocytes involves the processing and activation of caspases. Hepatology 1998;27:1632-1642.
54. 54. Rodriguez I, Matsuura K, Ody C, Nagita S, Vassalli P. Systemic injection of a tripeptide inhibits the intracellular activation of CPP32-like proteases in vivo and fully protects mice against Fas-mediated fulminant liver destruction and death. J Exp Med 1996;184:2067-2072.
55. 55. Lacronique V, et al. Bcl-2 protects from lethal hepatic apoptosis induced by an anti-Fas antibody in mice. Nat Med 1996;2:80-86.
56. 56. Kuida K, et al. Decreased apoptosis in the brain and premature lethality in CPP32 deficient mice. Nature 1996;384:368-372.
57. 57. Woo M, et al. Essential contribution of caspase 3/CPP32 to apoptosis and its associated nuclear changes. Genes Dev 1998;12:806-819.
58. 58. Kuida K, et al. Reduced apoptosis and cytochrome c-mediated caspase activation in juice lacking caspase 9. Cell 1998;94:325-337.
59. 59. Hakem R, et al. Differential requirement for caspase 9 in apoptotic pathways in vivo. Cell 1998;94:339-352.
60. 60. Bergeron L, et al. Defects in regulation of apoptosis in caspase-2-deficient mice. Genes Dev 1998;12:1304-1314.
61. 61. Yuan J, Shaham S, Ledoux S, Ellis HM, Horvitz HR. The C. elegans cell death gene ced-3 encodes a protein similar to mammalian interleukin 1 β-converting enzyme. Cell 1993;75:641-652.
62. 62. Gu Y, et al. Activation of interferon-γ inducing factor mediated by interleukin-1 β converting enzyme. Science 1997;275:206-209.
63. 63. Li P, et al. Mice deficient in II. 1 β-converting enzyme are defective in production of mature IL-1 β and resistant to endotoxic shock. Cell 1995;80:401-411.
64. 64. Wang S, et al. Identification and characterization of Ich-3, a member of the interleukin-1 β converting enzyme (ICE)/Ced-3 family and an upstream regulator of ICE. J Biol Chem 1996;271:20580-20587.
65. 65. Wang S, Miura M, Jung YK, Zhu H, Li E, Yuan J. Murine caspase-11, an ICE-interacting protease, is essential for the activation of ICE. Cell 1998;92:501-509.
66. 66. Veis DJ, Sorenson CM, Shutter JR, Korsmeyer SJ. Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair. Cell 1993;75:229-240.
67. 67. Nakayama K, et al. Disappearance of the lymphoid system in Bcl-2 homozygous mutant chimeric mice. Science 1993;261:1584-1588.
68. 68. Knudson CM, Tung KS, Tourtellotte WG, Brown WG, Korsmeyer SJ. Bax-deficient mice with lymphoid hyperplasia and male germ cell death. Science 1995;270:96-99.
69. 69. Knudson CM, Korsmeyer SJ. Bcl-2 and Bax function independently to regulate cell death. Nat Genet 1997;16:358-363.
70. 70. Motoyama N, et al. Massive cell death of immature hematopoietic cells and neurons in Bcl x-deficient mice. Science 1995;267:1506-1510.
71. 71. Ma A, et al. Bclx regulates the survival of double-positive thymocytes. Proc Natl Acad Sci USA 1995;92:4763-4767.
72. 72. Ross AJ, et al. Testicular degeneration in Bclw-deficient mice. Nat Genet 1998;18:251-256.
73. 73. Print CG, et al. Apoptosis regulator bcl-w is essential for spermatogenesis but appears otherwise redundant. Proc Natl Acad Sci USA 1998;95:12424-12431.
74. 74. Yoshida H, et al. Apaf1 is required for mitochondrial pathways of apoptosis and brain development. Cell 1998;94:739-750.
75. 75. Cecconi F, Alvarez-Bolado G, Meyer BI, Roth KA, Gruss P. Apaf1 (CED-4 homolog) regulates programmed cell death in mammalian development. Cell 1998;94:727-737.
76. 76. Bossy WE, Newmeyer DD, Green DR. Mitochondrial cytochrome c release in apoptosis occurs upstream of DEVD-specific caspase activation and independently of mitochondrial transmembrane depolarization. EMBO J 1998;17:37-49.
77. 77. Baker SJ, Reddy EP. Modulation of life and death by the TNF receptor superfamily. Oncogene 1998;17:3261-3270.
78. 78. Nagata S. Apoptosis by death factor. Cell 1997;88:355-365.
79. 79. Tewari M, Dixit VM. Recent advances in tumor necrosis factor and CD40 signaling. Curr Opin Genet Rev 1996;6:39-44.
80. 80. Varfolomeev EE, Boldin MP, Goncharov TM, Wallach D. A potential mechanism of "crosstalk" between the p55 tumor necrosis factor receptor and Fas/APO1: proteins binding to the death domains of the two receptors also bind to each other. J Exp Med 1996;183:1271-1275.
81. 81. Chinnaiyan AM, et al. FADD/MORT1 is a common mediator of CD95 (Fas/APO-1) and tumor necrosis factor receptor-induced apoptosis. J Biol Chem 1996;271:4961-4965.
82. 82. Chaudhary PM, Eby M, Jasmin A, Bookwalter A, Murray J, Hood L. Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-κB pathway. Immunity 1997;7:821-830.
83. 83. Kitson J, et al. A death-domain-containing receptor that mediates apoptosis. Nature 1996;384:372-375.
84. 84. Walczak H, et al. TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J 1997;16:5386-5397.
85. 85. Pan G, et al. The receptor for the cytotoxic ligand TRAIL. Science 1997;276:111-113.
86. 86. Pan G, et al. Identification and functional characterization of DR6, a novel death domain-containing TNF receptor. FEBS Lett 1998;431:351-356.
87. 87. Hsu H, Xiong J, Goeddel DV. The TNF receptor 1-associated protein TRADD signals cell death and NF-κ B activation. Cell 1995;81:495-504.
88. 88. Chinnaiyan AM, O'Rourke K, Tewari M, Dixit VM. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 1995;81:505-512.
89. 89. Stanger BZ, Leder P, Lee TH, Kim E, Seed B. RIP: a novel protein containing a death domain that interacts with Fas/APO-1 (CD95) in yeast and causes cell death. Cell 1995;81:513-523.
90. 90. Chinnaiyan AM, et al. Signal transduction by DR3, a death domain-containing receptor related to TNFR-1 and CD95. Science 1996;274:990-992.
91. 91. Hsu H, Shu HB, Pin MG, Goeddel DV. TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways. Cell 1996;84:299-308.
92. 92. Hsu H, Huang J, Shu HB, Baichwal V, Goeddel DV. TNF-dependent recruitment of the protein kinase RIP to the TNF receptor-1 signaling complex. Immunity 1996;4:387-396.
93. 93. Rothe M, Wong SC, Henzel WJ, Goeddel DV. A novel family of putative signal transducers associated with the cytoplasmic domain of the 75 kDa tumor necrosis factor receptor. Cell 1994;78:681-692.
94. 94. Rothe M, Pan MG, Henzel WJ, Ayres TM, Goeddel DV. The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins. Cell 1995;83:1243-1252.
95. 95. Cao Z, Xiong J, Takeuchi M, Kurama T, Goeddel DV. TRAF6 is a signal transducer for interleukin-1. Nature 1996;383:443-446.
96. 96. Cheng G, Cleary AM, Ye ZS, Hong DI, Lederman S, Baltimore D. Involvement of CRAF1, a relative of TRAF, in CD40 signaling. Science 1995;267:1494-1498.
97. 97. Regnier CH, et al. Presence of a new conserved domain in CART1, a novel member of the tumor necrosis factor receptor-associated protein family, which is expressed in breast carcinoma. J Biol Chem 1995;270:25715-25721.
98. 98. IshidaTK, et al. TRAFS, a novel tumor necrosis factor receptor-associated factor family protein, mediates CD40 signaling. Proc Natl Acad Sci USA 1996;93:9437-9442.
99. 99. Ishida T, et al. Identification of TRAF6, a novel tumor necrosis factor receptor-associated factor protein that mediates signaling from an amino-terminal domain of the CD40 cytoplasmic region. J Biol Chem 1996;271:28745-28748.
100. 100. Rothe M, Sarma V, Dixit VM, Goeddel DV, TRAF2-mediated activation of NF-κ B by TNF receptor 2 and CD40. Science 1995;269:1424-1427.
101. 101. Takeuchi M, Rothe M, Goeddel DV. Anatomy of TRAF2, Distinct domains for nuclear factor-κB activation and association with tumor necrosis factor signaling proteins. J Biol Chem 1996;271:19935-19342.
102. 102. Liu ZG, Hsu H, Goeddel DV, Karin M. Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosts while NF-κB activation prevents cell death. Cell 1996;87:565-576.
103. 103. Medema JP, et al. FLICE is activated by association with the CD95 death-inducing signaling complex (DISC). EMBO J 1997;16:2794-2804.
104. 104. Muzio M, et al. MICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell 1996;85:817-827.
105. 105. Boldin MP, Goncharov TM, Goltsev YV, Wallash D. Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1 - and TNF receptor-induced cell death. Cell 1996;85:803-815.
106. 106. Yang X, Khosravi-Far R, Chang HY, Baltimore D. Daxx, a novel Fas-binding protein that activates JNK and apoptosis. Cell 1997;89:1067-1076.
107. 107. Wang K, Yin XM, Chao DT, Milliman CL, Korsmeyer SJ. BID: a novel BH3 domain-only death agonist. Genes Dev 1996;10:2859-2869.
108. 108. Li H, Zhu H, Xu CJ, Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 1998;94:491-501.
109. 109. Luo X, Budihardjo I, Zou H, Slaughter C, Wang X. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 1998;94:481-490.
110. 110. Gross A, et al. Caspase cleaved BID targets mitochondria and is required for cytochrome c release, while BCL-XL prevents this release but not tumor necrosis factor-R1/Fas death. J Biol Chem 1999;274:1156-1163.
111. 111. Baeuerle PA, Baltimore D. NF-κB: ten years after. Cell 1996;87:13-20.
112. 112. Wang CY, Mayo MW, Baldwin AS Jr. TNF-and cancer therapy-induced apoptosis: potentiation by inhibition of NF-κB. Science 1996;274:784-787.
113. 113. Van Antwerp DJ, Martin SJ, Kafri T, Green DR. Verma IM. Suppression of TNF-α-induced apoptosis by NF-κB. Science 1996;274:787-799
114. 114. Beg AA, Baltimore. 1996. An essential role for NF-κB in preventing TNF-α-induced cell death. Science 1996;274:782-784.
115. 115. Natoli G, et al. Activation of SAPK/JNK by TNF receptor 1 through a noncytotoxic TRAF2-dependent pathway. Science 1997;275:200-203.
116. 116. Nishina H, et al. Stress-signalling kinase Sek 1 protects thymocytes from apoptosis mediated by CD95 and CD3. Nature 1997;385:350-353.
117. 117. Clem RJ, Miller LK. Control of programmed cell death by the baculovirus genes p35 and iap. Mol Cell Biol 1994;14:5212-5222.
118. 118. Roys N, Dcveraux QL, Takahashi R, Reed JC. 1997. The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases. EMBO J 1997;16:6914-6925.
119. 119. Deveraux QL, Takahashi R, Salvesen G, Reed JC. X-linked IAP is a direct inhibitor of cell-death proteases. Nature 1997;388:300-304.
120. 120. Duckett CS, Thompson CB. CD30-dependent degradation of TRAF2: implications for negative regulation of TRAF signaling and the control of cell survival. Genes Dev 1997;11:2810-2821.
121. 121. Boucher LM, Marengere LM, Lu Y, Thukral S, Mak TQ, Binding sites of cytoplasmic effectors TRAF1, 2, and 3 on CD30 and other members of the TNF receptor superfamily. Biochem Biophys Res Commun 1997;231:592-600.
122. 122. Aizawa S, et al. Tumor necrosis factor receptor-associated factor (TRAF) 5 and TRAF2 are involved in CD30-mediated NFκB activation. J Biol Chem 1997;272:2042-2045.
123. 123. Lee SY, Lee SY. Kandala G, Liou MI, Liou HC, Choi Y. CD30/TNF receptor-associated factor interaction: NF-κB activation and binding specificity. Proc Natl Acad Sci USA 1996;93:9699-9703.
124. 124. Gedrich RW, Gilfillan MC, Duckett CS, Van Dongen JL, Thompson CB. CD30 contains two binding sites with different .specificities for members of the tumor necrosis factor receptor-associated factor family of signal transducing proteins. J Biol Chem 1996;271:12852-12858.
125. 125. Ansieau S, et al. Tumor necrosis factor receptor-associated factor (TRAF)-1, TRAF-2, and TRAF-3 interact in vivo with the CD30 cytoplasmic domain; TRAF-2 mediates CD30-induced nuclear factor κ B activation [retracted in Proc Natl Acad Sci USA 1997;94:12732].
126. Proc Natl Acad Sci USA 1997;93:14053-14058.
127. 126. Darnay BG, Haridas V, Ni J, Moore PA, Aggarwal BB. Characterization of the intracellular domain of receptor activator of NF kB (RANK). J Biol Chem 1998;273:20551-20555.
128. 127. Wong BR, Josien R, Lee SY, Vologodskaia M, Steinman RM, Choi Y. The TRAF family of signal transducers mediates NF-κB activation by the TRANCE receptor. J Biol Chem 1998;273:28355-28359.
129. 128. Pullen SS, Miller HG, Everdeen DS, Dang TTS, Crute JJ, Kehry MR. CD40-tumor necrosis factor receptor-associated factor (TRAF) interactions; regulation of CD40 signaling through multiple TRAF binding sites and TRAF hetero-oligomerization. Biochemistry 1998;37:11836-11845.
130. 129. Galibert L, Tometsko ME, Anderson DM, Cosman D, Dougall WC. The involvement of multiple tumor necrosis factor receptor (TNFR)-associated factors in the signaling mechanisms of receptor activator of NF-κB, a member of the TNFR superfamily. J Biol Chem 1998;273:34120-34127.
131. 130. Grewal IS, Flavell RA, CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol 1998;16:111-135.
132. 131. Noelle RJ. CD40 and its ligand in host defense. Immunity 1996;4:415-419.
133. 132. Yeh WC, et al. FADD: essential for embryo development and signaling from some, but not all, inducers of apoptosis. Science 1998;279:1954-1958.
134. 133. Zhang J, Cado D, Chen A, Kabra NH, Winoto A. Fas-mediated apoptosis and activation-induced T cell proliferation are defective in mice lacking FADD/Mort1, Nature 1998;392:296-300.
135. 134. Balachandran S, Kim CN, Yeh WC, Mak TW, Bhalla K, Barber GN. Activation of the dsRNA-dependent protein kinase, PKR, induces apoptosis through FADD-mediated death signaling. EMBO J 1998;17:6888-6902.
136. 135. Varfolomeev EE, et al. Targeted disruption of the mouse caspase 8 gene ablates cell death induction by the TNF receptors, Fas/Apo1, and DR3 anil is lethal prenatally. Immunity 1998;9:267-276.
137. 136. Friesen C, Herr I, Krammer PH, Debatin KM. Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat Med 1996;2:574-577.
138. 137. Muller M, et al. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J Clin Invest 1997;99:403-413
139. 138. Hueber AO, Zornig M, Lyon D, Suda T, Nagau S, Evan GI. Requirement for the CD95 receptor-ligand pathway in c-Myc-induced apoptosis. Science 1997;278:1305-1309.
140. 139. Nguyen M, et al. E1A-induced processing of procaspase-8 can occur independently of FADD and is inhibited by Bcl-2. J Biol Chem 1998;273:33099-33102.
141. 140. Pfeffer K, et al. Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell 1993;73:457-467.
142. 141. Walsh CM, Wen BG, Chinnaiyan AM, O'Rourke K, Dixit VM, Hendrick SM. A role for FADD In T cell activation and development. Immunity 1998;8:439-449.
143. 142. Newton K, Harris AW, Bath ML, Smith KGC, Strasser A. A dominant interfering mutant of FADD/MORT1 enhances deletion of autoreactive thymocytes and inhibits proliferation ol mature T lymphocytes. EMBO J 1998;17:706-718.
144. 143. Zornig M, Hueber AO, Evan G. p53-dependent impairment of T-cell proliferation in FADD dominant-negative transgenic mice. Curr Biol 1998;8:467-470.
145. 144. Kolesnick RN, Kronke M. Regulation of ceramide production and apoptosis. Annu Rev Physiol 1998;60:643-665.
146. 145. Wiegmann K, Schwandner R, Krut O, Yeh WC, Mak TW, Kronke M. Requirement of FADD for TNF-induced activation of acid sphingomyelinase. J Biol Chem 1999;274:5267-5270.
147. 146. Yen WC, et al. Early lethality, functional NF κB activation, and increased sensitivity to TNF-induced cell death in TRAF2 deficient mice. Immunity 1997;7:715-725.
148. 147. Lee SY, Reichlin A, Santana A, Sokol KA, Nussenzweig MC, Choi Y, TRAF2 is essential for JNK but not NF-κB activation and regulates lymphocyte proliferation and survival. Immunity 1997;7:703-713.
149. 148. Lee SY, Kaufman DR, Mora AL, Santana A, Boothby M, Choi Y. Stimulus-dependent synergism of the antiapoptotic tumor necrosis factor receptor-associated factor 2 (TRAF2) and nuclear factor κB pathways. J Exp Med 1998;188:1381-1384.
150. 149. Kelliher MA, Grimm S, Ishida Y, Kuo F, Stanger BZ, Leder P. The death domain kinase RIP mediates the TNF-induced NF-κB signal. Immunity 1998;8:297-303.
151. 150. Probert L, et al. Wasting, ischemia, and lymphoid abnormalities in mice expressing T cell targeted human tumor necrosis factor transgenes. J Immunol 1993;151:1894-1906.
152. 151. Beutler B, Cerami A. Tumor necrosis, cachexia, shock and inflammation: a common mediator. Annu Rev Biochem 1988;57:505-518.
153. 152. Xu Y, Cheng G, Baltimore D, Targeted disruption of TRAF3 leads to postnatal lethality and defective T dependent immune responses. Immunity 1996;5:407-415.
154. 153. Malinin NL, Boldin MP, Kovalenko AV, Wallach D. MAP3K-related kinase involved in NF-κB induction by TNF, CD95 and IL-1. Nature 1997;385:540-544.
155. 154. Woronicz JD, Gao X, Cao Z, Rothe M, Goeddel DV. IκB kinase-β: NF-κB activation and complex formation with IκB kinase-α and NIK. Science 1997;278:866-869.
156. 155. Zandi E, Rothwarf DM, Delhase M, Hayakawa M, Karin M. The IκB kinase complex (IKK) contains two kinase subunits, IKKα and IKKβ, necessary for IκB phosphorylation and NF-κB activation. Cell 1997;91:243-252.
157. 156. Regnier CH. Song HY, Gao X, Goeddel DV, Cao Z, Rothe M. Identification and characterization of an IκB kinase. Cell 1997;90:373-383.
158. 157. Robinson D, et al. IGIF does not drive Th1 development but synorgizes with II.-12 for interferon-γ production and activates IRAK and NFκB. Immunity 1997;7:571-581.
159. 158. O'Neill LA, Greene C. Signal transduction pathways activated by the II.-1 receptor family: ancient signaling machinery in mammals, insects, and plants. J Leukoc Biol 1998;63:650-657.
160. 159. Wesche H, Korherr C, Kracht M, Falk W, Resch K, Martin MU. The interleukin-1 receptor accessory protein (IL-1RAcP) is essential for IL-1-induced activation of interleukin-1 receptor-associated kinase (IRAK) and stress-activated protein kinases (SAP kinases). J Biol Chem 1997;272:7727-7731.
161. 160. Wesche H, Henzel WJ, Shillinglaw W, Li S, Cao Z. MyD88: an adapter that recruits IRAK to the IL-1 receptor complex. Immunity 1997;7:837-847.
162. 161. Burns K, et al. MyD88, an adapter protein involved in interleukin-1 signaling. J Biol Chem 1998;273:12203-12209.
163. 162. Cao Z, Henzel WJ, Gao X. IRAK: a kinase associated with the interleukin-1 receptor. Science 1996;271:1128-1131.
164. 163. Muzio M, Ni J, Feng P, Dixit VM. IRAK (Pelle) family member IRAK-2 and MyD88 as proximal mediators of II.-1 signaling. Science 1997;278:1612-1615.
165. 164. Lomaga MA, et al. TRAF6-deficiency results in osteopetrosis and defective interleukin-1, CD40 and LPS signaling. Genes Dev 1999;13:1015-1024.
166. 165. Lacey DL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165-176.
167. 166. Anderson DM, et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic cell function. Nature 1997;390:175-179.
168. 167. Simonet WS, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89:309-319.
169. 168. Wang Z-Q, Ovitt C, Grigoriadis AE, Mohle-Steinlein U, Ruther U, Wagner EF. Bone and haematopoietic defects in mice lacking c-Fos. Nature 1992;360:741-745.
170. 169. Tondravi MM, et al. Osteopetrosis in mice lacking haematopoietic transcription factor PU. 1. Nature 1997;386:81-84.
171. 170. Insogna KL, et al. Colony-stimulaling factor-1 induces cytoskeletal reorganization and c-src-dependent tyrosine phosphorylation of selected cellular proteins in rodent osteoclasts. J Clin Invest 1997;100:2476-2485.
172. 171. Grigoriadis AE, et al. c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science 1996;266:443-438.
173. 172. Franzoso G, et al. Requirement for NF-κB in osteoclast and B-cell development. Genes Dev 1997;11:3482-3496.
174. 173. Kong YY, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999;397:315-323.
175. 174. Soriano P, Montgomery C, Geske R, Bradley A. Targeted disruption of the c-src protooncogene leads to osteopetrosis in mice. Cell 1991;64:693-702.
176. 175. Poltorak A, et al. Defective LPS signaling in C3H/HeJ and C57BI./10ScCr mice: mutations in TLR4 gene. Science 1998;282:2085-2088.
177. 176. Kirschning CJ, Wesche H, AyresTM, Rothe M. Human Toll-like receptor 2 confers responsiveness to bacterial LPS. J Exp Med 1998;188:2091-2097.
178. 177. Yang R-B, et al. Toll-like receptor-2 mediates lipopolysaccharide induced cellular signalling. Nature 1998;395:284-288.
179. 178. Thornberry NA. Caspases: key mediators of apoptosis. Chem Biol 1998;5:R97-R103.
180. 179. Rouquet N, Pages JC, Molina T, Briand P, Joulin V. ICE inhibitor YVADcmk is a potent therapeutic agent against in vivo liver apoptosis. Curr Biol 1996,6:1192-1195.
181. 180. Longthorne VI, Williams GT. Caspase activity is required for commitment to Fas-mediated apoptosis. EMBO J 1997;16:3805-3812.
182. 181. Cheng Y, et al. Caspase inhibitor affords neuroprotection with delayed administration in a rat model of neonatal hypoxic ischemic brain injury. J Clin Invest 1998;101:1992-1999.
183. 182. Loddick SA, MacKenzie A, Rothwell NJ. An ICE inhibitor, z-VAD-DCB attenuates ischaemic brain damage in the rat. Neuroreport 1996;7:1465-1468.
184. 183. Garcia-Calvo M, Peterson EP, Leiting B, Ruel R, Nicholson DW, Thomberry NA. Inhibition of human caspases by peptide-based and macromolecular inhibitors. J Biol Chem 1998;273:32608-32613.